{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:14:44Z","timestamp":1780636484258,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Science Research Promotion Fund","award":["42"],"award-info":[{"award-number":["42"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40261-019-00754-z","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T04:33:06Z","timestamp":1548649986000},"page":"363-368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8882-8846","authenticated-orcid":false,"given":"Keiko","family":"Hosohata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iku","family":"Niinomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.seizure.2013.02.012","volume":"22","author":"A Vel Van de","year":"2013","unstructured":"Van de Vel A, Cuppens K, Bonroy B, Milosevic M, Jansen K, Van Huffel S, et al. Non-eeg seizure-detection systems and potential sudep prevention: state of the art. Seizure. 2013;22:345\u201355.","journal-title":"Seizure"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1212\/WNL.0b013e31822cfc90","volume":"77","author":"AK Ngugi","year":"2011","unstructured":"Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of epilepsy: a systematic review and meta-analysis. Neurology. 2011;77:1005\u201312.","journal-title":"Neurology"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.yebeh.2015.11.009","volume":"54","author":"AB Kowski","year":"2016","unstructured":"Kowski AB, Weissinger F, Gaus V, Fidzinski P, Losch F, Holtkamp M. Specific adverse effects of antiepileptic drugs\u2013a true-to-life monotherapy study. Epilepsy Behav. 2016;54:150\u20137.","journal-title":"Epilepsy Behav"},{"key":"754_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314\u20139.","journal-title":"N Engl J Med"},{"key":"754_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","volume":"72","author":"P Perucca","year":"2009","unstructured":"Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72:1223\u20139.","journal-title":"Neurology"},{"key":"754_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","volume":"68","author":"MJ Brodie","year":"2007","unstructured":"Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402\u20138.","journal-title":"Neurology"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","volume":"58","author":"S Halevy","year":"2008","unstructured":"Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis in europe and israel. J Am Acad Dermatol. 2008;58:25\u201332.","journal-title":"J Am Acad Dermatol"},{"key":"754_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/epi.12926","volume":"56","author":"KJ Werhahn","year":"2015","unstructured":"Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56:450\u20139.","journal-title":"Epilepsia"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/ane.12162","volume":"128","author":"E Trinka","year":"2013","unstructured":"Trinka E, Giorgi L, Patten A, Segieth J. Safety and tolerability of zonisamide in elderly patients with epilepsy. Acta Neurol Scand. 2013;128:422\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"754_CR10","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/bcp.13693","volume":"84","author":"J Mahe","year":"2018","unstructured":"Mahe J, de Campaigno EP, Chene AL, Montastruc JL, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors: identification of suspicious targets by disproportionality analysis from Vigibase. Br J Clin Pharmacol. 2018;84(10):2373\u201383.","journal-title":"Br J Clin Pharmacol"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jcpt.12148","volume":"39","author":"D Mendes","year":"2014","unstructured":"Mendes D, Alves C, Batel-Marques F. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. J Clin Pharm Therap. 2014;39:307\u201313.","journal-title":"J Clin Pharm Therap"},{"issue":"1","key":"754_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/jcpt.12748","volume":"44","author":"K Hosohata","year":"2019","unstructured":"Hosohata K, Inada A, Oyama S, Furushima D, Yamada H, Iwanaga K. Surveillance of drugs that most frequently induce acute kidney injury: a pharmacovigilance approach. J Clin Pharm Therap. 2019;44(1):49\u201353.","journal-title":"J Clin Pharm Therap"},{"issue":"10","key":"754_CR13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/jcph.1147","volume":"58","author":"M Gosho","year":"2018","unstructured":"Gosho M. Risk of hypoglycemia after concomitant use of antidiabetic, antihypertensive, and antihyperlipidemic medications: a database study. J Clin Pharmacol. 2018;58(10):1324\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"754_CR14","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1177\/0300060518786917","volume":"46","author":"K Hosohata","year":"2018","unstructured":"Hosohata K, Matsuoka E, Inada A, Oyama S, Niinomi I, Mori Y, et al. Differential profiles of adverse events associated with mycophenolate mofetil between adult and pediatric renal transplant patients. J Int Med Res. 2018;46(11):4617\u201323.","journal-title":"J Int Med Res"},{"key":"754_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2147\/TCRM.S168696","volume":"14","author":"S Oyama","year":"2018","unstructured":"Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, et al. Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Therap Clin Risk Manag. 2018;14:1599\u2013604.","journal-title":"Therap Clin Risk Manag"},{"key":"754_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/jcpt.12683","volume":"43","author":"E Kose","year":"2018","unstructured":"Kose E. Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database. J Clin Pharm Therap. 2018;43:543\u20139.","journal-title":"J Clin Pharm Therap"},{"issue":"1","key":"754_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/pcn.12793","volume":"73","author":"T Anzai","year":"2019","unstructured":"Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. Psychiatry Clin Neurosci. 2019;73(1):27\u201333.","journal-title":"Psychiatry Clin Neurosci"},{"key":"754_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous adr reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"754_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/pds.3529","volume":"23","author":"F Maignen","year":"2014","unstructured":"Maignen F, Hauben M, Hung E, Van Holle L, Dogne JM. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf. 2014;23:195\u2013207.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"754_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","volume":"52","author":"D Italiano","year":"2013","unstructured":"Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52:627\u201345.","journal-title":"Clin Pharmacokinet"},{"key":"754_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40266-017-0465-7","volume":"34","author":"J Theitler","year":"2017","unstructured":"Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R. Antiepileptic drug treatment in community-dwelling older patients with epilepsy: a retrospective observational study of old- versus new-generation antiepileptic drugs. Drugs Aging. 2017;34:479\u201387.","journal-title":"Drugs Aging"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.eplepsyres.2017.11.007","volume":"139","author":"NA Mohd-Tahir","year":"2018","unstructured":"Mohd-Tahir NA, Li SC. Meta-analyses of newer antiepileptic drugs as adjunct for treatment of focal epilepsy in children. Epilepsy Res. 2018;139:113\u201322.","journal-title":"Epilepsy Res"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/j.1528-1167.2007.01109.x","volume":"48","author":"S Alvestad","year":"2007","unstructured":"Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: Influence by gender, age, and learning disability. Epilepsia. 2007;48:1360\u20135.","journal-title":"Epilepsia"},{"key":"754_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000\u201315.","journal-title":"Lancet"},{"key":"754_CR25","doi-asserted-by":"publisher","first-page":"e0131566","DOI":"10.1371\/journal.pone.0131566","volume":"10","author":"QY Zeng","year":"2015","unstructured":"Zeng QY, Fan TT, Zhu P, He RQ, Bao YX, Zheng RY, et al. Comparative long-term effectiveness of a monotherapy with five antiepileptic drugs for focal epilepsy in adult patients: a prospective cohort study. PLoS One. 2015;10:e0131566.","journal-title":"PLoS One"},{"key":"754_CR26","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","volume":"333","author":"JC Roujeau","year":"1995","unstructured":"Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens\u2013Johnson Syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600\u20137.","journal-title":"N Engl J Med"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","volume":"128","author":"M Mockenhaupt","year":"2008","unstructured":"Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson Syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The euroscar-study. J Investig Dermatol. 2008;128:35\u201344.","journal-title":"J Investig Dermatol"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","volume":"64","author":"M Mockenhaupt","year":"2005","unstructured":"Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134\u20138.","journal-title":"Neurology"},{"key":"754_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.14581\/jer.15015","volume":"5","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Son JM, Mun J, Kim DW. Safety and efficacy of zonisamide in patients with epilepsy: a post-marketing surveillance study. J Epilepsy Res. 2015;5:89\u201395.","journal-title":"J Epilepsy Res"},{"key":"754_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2165\/00002018-199921060-00005","volume":"21","author":"SR Knowles","year":"1999","unstructured":"Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999;21:489\u2013501.","journal-title":"Drug Saf"},{"key":"754_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.eplepsyres.2011.02.005","volume":"94","author":"XQ Wang","year":"2011","unstructured":"Wang XQ, Shi XB, Au R, Chen FS, Wang F, Lang SY. Influence of chemical structure on skin reactions induced by antiepileptic drugs\u2014the role of the aromatic ring. Epilepsy Res. 2011;94:213\u20137.","journal-title":"Epilepsy Res"},{"key":"754_CR32","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1124\/dmd.107.015271","volume":"35","author":"W Lu","year":"2007","unstructured":"Lu W, Uetrecht JP. Possible bioactivation pathways of lamotrigine. Drug Metab Dispos. 2007;35:1050\u20136.","journal-title":"Drug Metab Dispos"},{"key":"754_CR33","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1067\/mai.2003.1507","volume":"111","author":"DJ Naisbitt","year":"2003","unstructured":"Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific t cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393\u2013403.","journal-title":"J Allergy Clin Immunol"},{"key":"754_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/WCO.0b013e328328f276","volume":"22","author":"D Franciotta","year":"2009","unstructured":"Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol. 2009;22:144\u20139.","journal-title":"Curr Opin Neurol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00754-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00754-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00754-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T19:11:30Z","timestamp":1580152290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00754-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00754-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"28 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Keiko Hosohata received research support from the Science Research Promotion Fund (Grant no. 42).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Keiko Hosohata, Ayaka Inada, Saki Oyama, Iku Niinomi, Tomohito Wakabayashi and Kazunori Iwanaga report no conflicts of interest related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}